Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy
Por un escritor de hombre misterioso
Descripción
A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy
The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCL
The heightened importance of the microbiome in cancer immunotherapy: Trends in Immunology
A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy
Role of gut microbiome in cancer immunotherapy: from predictive biomarker to therapeutic target, Experimental Hematology & Oncology
Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy
Cancers, Free Full-Text
Cancers, Free Full-Text
Infectious complications of CAR T-cell therapy: a clinical update - Adam G. Stewart, Andrea S. Henden, 2021
CAR-T cell therapy-related cytokine release syndrome and therapeutic response is modulated by the gut microbiome in hematologic malignancies
de
por adulto (el precio varía según el tamaño del grupo)